韩国医保体系下渗出性年龄相关性黄斑变性的发病率与治疗负荷
6年发病率为2.9/万人年(95%CI 2.8-3.0),75-79岁最高(12.0/万人年),男性高于女性;912例新诊断患者中69%起始抗VEGF治疗,平均注射6.1次。
要点
- ≥40岁人群6年渗出性AMD发病率为2.9/万人年(95%CI 2.8-3.0)。
- 75-79岁发病率最高(12.0/万人年),所有年龄组男性均高于女性。
- 新诊断患者中69%起始雷珠单抗或阿柏西普,平均注射6.1次。
核心结论
- 研究描述了韩国国民健康保险体系下渗出性AMD的发病率及抗VEGF治疗负荷。
研究设计与样本
- 以罕见难治性疾病登记码定义新发渗出性AMD,估算每万人年发病率及95%CI。
主要发现
- 2010-2015年共912例新诊断渗出性AMD,6年发病率为2.9/万人年(95%CI 2.8-3.0)。
- 75-79岁发病率最高(12.0,95%CI 10.3-13.8),所有年龄组男性发病率均高于女性。
- 2010-2015年平均注射6.1次(SD 3.9;最少1次,最多为政府支持上限14次),随政府资金支持增加而增加(2013年从5增至10,2014年从10增至14)。
关键数值与推荐
- 渗出性AMD发病率:≥40岁人群2.9/万人年(95%CI 2.8-3.0)。
- 年龄别最高发病率:75-79岁12.0/万人年(95%CI 10.3-13.8)。
- 平均注射次数:6.1次(SD 3.9),范围1至政府支持上限14次。
临床怎么用
- 研究结果可作为渗出性AMD治疗规划及医保政策制定的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: The aim of this study was to estimate the nationwide incidence of clinically diagnosed exudative age-related macular degeneration (AMD) and associated use of ranibizumab and aflibercept in South Korea. METHODS: In this retrospective, population-based cohort study, claims data for 2010-2015 were analysed in a randomly selected sample of 519 661 adults aged ≥40 years. The incidence per 10 000 person-years was estimated, along with the 95% CI. Incident exudative AMD was defined based on the registration code for rare intractable diseases. Use of ranibizumab and aflibercept and the incidence of exudative AMD were recorded. RESULTS: Nine hundred and twelve patients were newly diagnosed with exudative AMD in 2010-2015. The 6-year incidence in the general population aged ≥40 years was 2.9 (95% CI 2.8 to 3.0) per 10 000 person-years. The incidence was highest in individuals aged 75-79 years (12.0, 95% CI 10.3 to 13.8). The incidence was higher in men than in women in all age groups. Six hundred and twenty-five (69%) of the 912 newly diagnosed patients started ranibizumab or aflibercept as a first-line treatment. The average number of injections administered was 6.1 (SD 3.9; minimum of 1 injection and maximum government-supported limit of 14) during 2010-2015; the number increased with increasing government funding support (from 5 to 10 and from 10 to 14 in 2013 and 2014, respectively). CONCLUSIONS: This study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD.
引用
- Rim TH, Yoo TK, Kim SH, et al. Incidence of exudative age-related macular degeneration and treatment load under the Korean national health insurance system in 2010-2015. Br J Ophthalmol. 2018. PMID: 30573498. doi:10.1136/bjophthalmol-2018-312693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。